Advertisement

Leukemia Drug Iclusig, Suspended Over Rise in Thromboses, Ready to Re-emerge — Physician’s First Watch

Medical News |
December 23, 2013

Leukemia Drug Iclusig, Suspended Over Rise in Thromboses, Ready to Re-emerge

By the Editors

The makers of Iclusig (ponatinib) will comply with several FDA-mandated safety measures to address risks for life-threatening thromboses and blood-vessel narrowing, and marketing is expected to resume by the end of January, the FDA said late last week.

The drug, a kinase inhibitor, had been used in chronic myeloid leukemia and Philadelphia-chromosome-positive acute lymphoblastic leukemia before its suspension in late October over "a steady increase in the number of serious vascular occlusion events" in patients.

Your Comment

(will not be published)

Filtered HTML

  • Allowed HTML tags: <a> <em> <strong> <cite> <blockquote> <code> <ul> <ol> <li> <dl> <dt> <dd>
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.
Do you have any conflict of interest to disclose?
CAPTCHA
This question is for testing whether you are a human visitor and to prevent automated spam submissions.
Image CAPTCHA
Enter the characters shown in the image.

Vertical Tabs

* Required

Reader comments are intended to encourage lively discussion of clinical topics with your peers in the medical community. We ask that you keep your remarks to a reasonable length, and we reserve the right to withhold publication of remarks that do not meet this standard.

PRIVACY: We will not use your email address, submitted for a comment, for any other purpose nor sell, rent, or share your e-mail address with any third parties. Please see our Privacy Policy.

Advertisement
Advertisement
Advertisement